Renin-Angiotensin-Aldosterone Inhibitors and COVID-19

• There is a concern that renin–angiotensin–aldosterone system (RAAS) blockers increase susceptibility to coronavirus 2019 (COVID-19). • There no evidence that treatment with RAAS blockers worsens the course of COVID-19. • Discontinuation of RAAS blockers may exacerbate cardiovascular comorbidities....

Descripción completa

Detalles Bibliográficos
Autores principales: Benenson, Irina, Waldron, Frederick Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7237918/
https://www.ncbi.nlm.nih.gov/pubmed/32834792
http://dx.doi.org/10.1016/j.nurpra.2020.05.007
_version_ 1783536423844970496
author Benenson, Irina
Waldron, Frederick Andrew
author_facet Benenson, Irina
Waldron, Frederick Andrew
author_sort Benenson, Irina
collection PubMed
description • There is a concern that renin–angiotensin–aldosterone system (RAAS) blockers increase susceptibility to coronavirus 2019 (COVID-19). • There no evidence that treatment with RAAS blockers worsens the course of COVID-19. • Discontinuation of RAAS blockers may exacerbate cardiovascular comorbidities. • RAAS blockers should be continued in patients with otherwise stable conditions.
format Online
Article
Text
id pubmed-7237918
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-72379182020-05-20 Renin-Angiotensin-Aldosterone Inhibitors and COVID-19 Benenson, Irina Waldron, Frederick Andrew J Nurse Pract Article • There is a concern that renin–angiotensin–aldosterone system (RAAS) blockers increase susceptibility to coronavirus 2019 (COVID-19). • There no evidence that treatment with RAAS blockers worsens the course of COVID-19. • Discontinuation of RAAS blockers may exacerbate cardiovascular comorbidities. • RAAS blockers should be continued in patients with otherwise stable conditions. Elsevier Inc. 2020 2020-05-20 /pmc/articles/PMC7237918/ /pubmed/32834792 http://dx.doi.org/10.1016/j.nurpra.2020.05.007 Text en © 2020 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Benenson, Irina
Waldron, Frederick Andrew
Renin-Angiotensin-Aldosterone Inhibitors and COVID-19
title Renin-Angiotensin-Aldosterone Inhibitors and COVID-19
title_full Renin-Angiotensin-Aldosterone Inhibitors and COVID-19
title_fullStr Renin-Angiotensin-Aldosterone Inhibitors and COVID-19
title_full_unstemmed Renin-Angiotensin-Aldosterone Inhibitors and COVID-19
title_short Renin-Angiotensin-Aldosterone Inhibitors and COVID-19
title_sort renin-angiotensin-aldosterone inhibitors and covid-19
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7237918/
https://www.ncbi.nlm.nih.gov/pubmed/32834792
http://dx.doi.org/10.1016/j.nurpra.2020.05.007
work_keys_str_mv AT benensonirina reninangiotensinaldosteroneinhibitorsandcovid19
AT waldronfrederickandrew reninangiotensinaldosteroneinhibitorsandcovid19

Ejemplares similares